Form 8-K CYTOKINETICS INC For: Feb 09

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. DFTX
10. NKE

February 10, 2015 4:39 PM EST
�

�

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section�13 or 15(d) of the Securities Exchange Act of 1934

� � �
Date of Report (Date of Earliest Event Reported): � February 9, 2015

Cytokinetics, Incorporated
__________________________________________
(Exact name of registrant as specified in its charter)

� � �
Delaware 000-50633 94-3291317
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
�� � �
280 East Grand Avenue, South San Francisco, California � 94080
_________________________________
(Address of principal executive offices) 		� ___________
(Zip Code)
� � �
Registrant�s telephone number, including area code: � (650) 624 - 3000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

�

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[��]��Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[��]��Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[��]��Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[��]��Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On February 9, 2015, Denise M. Gilbert, Ph.D. provided notice to Cytokinetics, Incorporated (the "Company") that she will not stand for re-election to the Company’s Board of Directors (the "Board") at the Company's Annual Meeting of Stockholders, which will occur on May 20, 2015. Dr. Gilbert has indicated she will continue her service on the Board until the expiration of her current term. Dr. Gilbert's resignation is not the result of any disagreement with the Board or the Company's management.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

� � � � �
� � Cytokinetics, Incorporated
�� � � � �
February 10, 2015 � By: � /s/ Sharon A. Barbari
� � � �
� � � � Name: Sharon A. Barbari
� � � � Title: Executive Vice President, Finance and Chief Financial Officer

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings